Testosterone replacement therapy

CPD
By
Tim Stewart MPharm
-

References 

  1. Allan CA, McLachlan RI. Testosterone deficiency in men: diagnosis and management, Australian Family Physician 2003;32(6):422–27. 
  2. Tyagi V, Scordo M, Yoon RS, et al. Revisiting the role of testosterone: are we missing something? Rev Urol 2017;19(1):16–24. 
  3. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 2009;5:427–48. 
  4. Corradi PF, Corradi RB, Greene LW. Physiology of the hypothalamic pituitary gonadal axis in the male. Urologic Clinics of North America 2016;43(2):151–62. 
  5. Maiburg M, Repping S, Giltay J. The genetic origin of Klinefelter syndrome and its effect on spermatogenesis. Fertil Steril 2012;98(2):253–60.  
  6. Bourke E, Herlihy A, Snow P, et al. Klinefelter syndrome – a general practice perspective. Aust Fam Physician 2014;43(1)38–41. 
  7. Anderson JK, Faulkner S, Cranor C, et al. Andropause: knowledge and perceptions among the general public and health care professionals. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2002;57(12):M793-M796.  
  8. Corona G, Sforza A, Maggi M. Testosterone replacement therapy: long-term safety and efficacy. World J Men’s Health 2017;35(2):65–76.  
  9. Androgen deprivation therapy (ADT) for prostate cancer | eviQ. NSW Government. 2017; At: www.eviq.org.au/patients-and-carers/patient-information-sheets/treating-cancer-with-medicines/3384-androgen-deprivation-therapy-adt-for-prosta on 18 August 2024 
  10. eMIMS cloud. Sydney: MIMS Australia; 2024.  
  11. Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int 2013;111(4):543–8. 
  12. Nolan BJ, Zwickl S, Locke P et al. Early access to testosterone therapy in transgender and gender-diverse adults seeking masculinization. JAMA Netw Open 2023;6(9):e2331919.  
  13. Cundill P. Hormone therapy for trans and gender diverse patients in the general practice setting. Aust J Gen Pract 2020;49(7):385–90.  
  14. Sullivan MV, Fletcher C, Armitage R, et al. A rapid synthesis of molecularly imprinted polymer nanoparticles for the extraction of performance enhancing drugs (PIEDs). Nanoscale Advances 2023;5(19):5352–60.  
  15. Alcohol and Drug Foundation website. Performance & image enhancing drugs (PIEDs). 20 June 2024. At: https://adf.org.au/drug-facts/pieds  
  16. James E, Wynn LL. Testosterone vs. steroids: comparing the disciplined bodywork projects of performance and image enhancing drug users in Australia. Int J Drug Policy 2022;107:103776.  
  17. Pope HG, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev 2014;35(3):341–75.  
  18. Chan I, Ng Tang Fui M, Zajac JD, et al. Assessment and management of male androgen disorders: an update. Aust Fam Physician 2014:43(5):277–82.  
  19. Yeap BB, Grossmann M, McLachlan RI, et al. Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations. Med J Aust 2016;205(5):228–231.  
  20. The Pharmaceutical Benefits Scheme (PBS) website. Australian Government Department of Health and Aged Care; 2024. At: www.pbs.gov.au/pbs/home